Benitec Biopharma (BNTC) Prices 29.8M Share Offering at $0.60/sh

Benitec Biopharma Inc. (Nasdaq: BNTC) today announced the pricing of its underwritten public offering of 29,809,471 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 29,809,471 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one common warrant to purchase one share of common stock at a combined offering price of $0.60. The warrants will be exercisable commencing on the effective date of an increase in our authorized shares of common stock at an exercise price of $0.66 per share of common stock and will expire on the fifth anniversary of such initial exercise date. The offering is expected to close on September 15, 2022, subject to customary closing conditions.

The aggregate gross proceeds to Benitec from the public offering are expected to be approximately $17.9 million prior to deducting underwriting discounts, commissions and other estimated offering expenses. The Company intends to use the net proceeds from this financing for the clinical development of BB-301, including the natural history lead-in study and the Phase 1b/2a BB-301 treatment study, for the continued advancement of development activities for other existing and new product candidates, for general corporate purposes and for strategic growth opportunities.

JMP Securities, A Citizens Company, is acting as sole book-running manager for the offering.

The Securities and Exchange Commission (“SEC”) declared effective registration statements on Form S-1 relating to these securities (other than the shares of common stock issuable upon exercise of the common warrants) on September 12, 2022. A final prospectus relating to this offering will be filed with the SEC. The offering is being made only by means of a prospectus. Copies of the prospectus relating to the offering may be obtained, when available, from JMP Securities LLC, 600 Montgomery Street, 10th Floor, San Francisco, CA 94111, Attention: Prospectus Department, or by calling (415) 835-8985, or by email at [email protected]. Investors may also obtain these documents at no cost by visiting the SEC’s website at http://www.sec.gov.

Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more complete information about the Company and the offering.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• enVVeno Medical (NVNO) files $100M mixed shelf
• Gossamer Bio raises up to $250M in private placement for PAH drug
• Kairos Pharma announces 1-for-7 reverse stock split